Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where asbestos has been used for industrial applications. Notwithstanding the progress made in the field, patients do not survive more than 12 months on average with standard treatment. With the advent of next generation sequencing, it is now possible to study the mutational landscape of each tumor with the aim of identifying the genetic aberrations driving tumorigenesis. This review encompasses the latest research in the field, with particular attention to new chemotherapy combinatorial regimens, molecular targets and immunotherapies, providing a comprehensive picture of the current and future treatment options for malignant mesothelioma patients.

Advances in systemic therapy for malignant mesothelioma: future perspectives / Sobhani N; Corona SP; Bonazza D; Ianza A; Pivetta T; Roviello G; Cortale M; Guglielmi A; Zanconati F; Generali D. - In: FUTURE ONCOLOGY. - ISSN 1479-6694. - 13:(2017), pp. 2083-2101. [10.2217/fon-2017-0224]

Advances in systemic therapy for malignant mesothelioma: future perspectives

Roviello G;
2017

Abstract

Malignant mesothelioma is a rare and aggressive form of cancer affecting the mesothelium. This mainly occupational disease is becoming more common in those countries where asbestos has been used for industrial applications. Notwithstanding the progress made in the field, patients do not survive more than 12 months on average with standard treatment. With the advent of next generation sequencing, it is now possible to study the mutational landscape of each tumor with the aim of identifying the genetic aberrations driving tumorigenesis. This review encompasses the latest research in the field, with particular attention to new chemotherapy combinatorial regimens, molecular targets and immunotherapies, providing a comprehensive picture of the current and future treatment options for malignant mesothelioma patients.
2017
13
2083
2101
Sobhani N; Corona SP; Bonazza D; Ianza A; Pivetta T; Roviello G; Cortale M; Guglielmi A; Zanconati F; Generali D
File in questo prodotto:
File Dimensione Formato  
Future oncology 23.pdf

Accesso chiuso

Dimensione 9.35 MB
Formato Adobe PDF
9.35 MB Adobe PDF   Richiedi una copia

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1156809
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact